Italia markets closed
FTSE MIB
35.398,82 -11,31 (-0,03%) Dow Jones
39.913,88 +44,50 (+0,11%) Nasdaq
16.639,23 -59,09 (-0,35%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
80,01 +0,78 (+0,98%) Bitcoin EUR
61.165,51 +1.424,68 (+2,38%)
UCB SA (UNC.MU)
Munich - Munich Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 08:00AM CEST. Mercato aperto.
| Chiusura precedente | 122,75 |
| Aperto | 121,05 |
| Denaro | 124,00 x 0 |
| Lettera | 125,25 x 0 |
| Min-Max giorno | 121,05 - 121,05 |
| Intervallo di 52 settimane | 65,54 - 125,10 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 24 lug 2024 - 03 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno
© 2024 Yahoo. Tutti i diritti riservati.